N-Myc is overexpressed in approximately 25% of neuroblastomas and is associated with aggressive disease progression and poor outcomes 14, emphasizing its potential as a valuable therapeutic target for N-Myc-dependent cancers 15, 16. This evidence concerns the gene MYCN and cancer.